Drug Trial Radar · NCT05409066
Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and Oral Lenalidomide (R2) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Follicular Lymphoma
Last checked: Nov 20, 2026Latest source record: Jul 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
549
Actual
Start
Sep 20, 2022
Primary completion
Dec 2029
Study completion Dec 2029
Sponsor
- Lead sponsor
- GenmabIndustry
- Sponsor type
- Industry
- Collaborators
- AbbVie
- First posted
- Jun 8, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Follicular Lymphoma (FL) is the second most common B-cell cancer and the most common type of cancer of lymphocytes. Unfortunately, this disease is incurable with conventional treatment and the disease recurs in almost all patients. This study will assess how safe and effective epcoritamab is in combination with lenalidomide and rituximab (R2) in treating adult participants with relapsed or refractory (R/R) FL. Adverse events and change in disease condition will be assessed. Epcoritamab is an investigational drug being developed for the treatment of FL. Study doctors put the participants in 1 of 3 groups, called treatment arms. Each group receives a different treatment. Enrollment to one of the groups is closed. Around 500 adult participants with R/R FL will be enrolled in approximately 300 sites across the world. Participants will receive R2 (375 mg/m\^2 intravenous infusion of rituximab up to 5 cycles and oral capsules of 20 mg lenalidomide for up to 12 cycles) alone or in combination with subcutaneous injections of epcoritamab for up to 12 cycles (each cycle is 28 days). There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, checking for side effects and completing questionnaires.
Conditions
- Follicular Lymphoma (FL)
Interventions
EpcoritamabDrug
Subcutaneous Injection
RituximabDrug
Intravenous Infusion
LenalidomideDrug
Oral Capsules
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Achieving Best Overall Response (BOR)Time frame: Up to approximately 2 years and 3 months
- Progression-Free Survival (PFS)Time frame: Up to approximately 2 years and 3 months
Locations
273 sites in 30 countries. Site status is shown where the registry gives one.
The University of Arizona Cancer Center - North Campus /ID# 228862
Tucson, Arizona
University of Arkansas for Medical Sciences /ID# 227198
Little Rock, Arkansas
Alta Bates Summit Medical Center for Research /ID# 229428
Berkeley, California
Beverly Hills Cancer Center /ID# 231535
Beverly Hills, California
Long Beach Memorial Medical Ct /ID# 228997
Long Beach, California
University of Southern California /ID# 227195
Los Angeles, California
Valkyrie Clinical Trials /ID# 268502
Los Angeles, California
Duplicate_Emory University /ID# 227299
Atlanta, Georgia
Hawaii Cancer Care - Waterfront Plaza /ID# 262448
Honolulu, Hawaii
Northwestern University Feinberg School of Medicine /ID# 227248
Chicago, Illinois
Goshen Center for Cancer Care /ID# 227189
Goshen, Indiana
Community Health Network, Inc. /ID# 259756
Indianapolis, Indiana
Our Lady Of The Lake Regional Medical Center /ID# 251393
Baton Rouge, Louisiana
University of Maryland, Baltimore /ID# 227191
Baltimore, Maryland
Massachusetts General Hospital /ID# 245233
Boston, Massachusetts
UMass Memorial Medical Center /ID# 227323
Worcester, Massachusetts
Henry Ford Hospital /ID# 227250
Detroit, Michigan
St. Luke's Hospital - Chesterfield /ID# 247817
Chesterfield, Missouri
Intermountain Health St. Vincent Regional Hospital - Cancer Centers of Montana /ID# 251220
Billings, Montana
Morristown Medical Center /ID# 231427
Morristown, New Jersey
Roswell Park Cancer Institute /ID# 239128
Buffalo, New York
NYU Langone Hospital - Long Island /ID# 253343
Mineola, New York
NYU Laura and Isaac Perlmutter Cancer Center /ID# 227322
New York, New York
Icahn School of Medicine at Mount Sinai /ID# 227181
New York, New York
Memorial Sloan Kettering Cancer Center-Koch Center /ID# 227193
New York, New York
East Carolina University - Brody School of Medicine /ID# 227192
Greenville, North Carolina
University of Oklahoma, Stephenson Cancer Center /ID# 227325
Oklahoma City, Oklahoma
Baylor Sammons Cancer Center /ID# 261584
Dallas, Texas
Texas Oncology - Northeast Texas /ID# 265890
Tyler, Texas
Intermountain Healthcare LDS Hospital /ID# 259948
Salt Lake City, Utah
Virginia Commonwealth University Medical Center Main Hospital /ID# 227211
Richmond, Virginia
Hospital Privado Universitario - Hospital Privado Centro Medico de Cordoba S.A. /ID# 229701
Córdoba, Argentina
Clinica de Nefrologia, Urologia y Enfermedades Cardiovasculares /ID# 232124
Santa Fe, Argentina
Fundaleu /Id# 229700
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
Duplicate_CEMIC /ID# 229697
Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina
Royal Prince Alfred Hospital /ID# 239272
Camperdown, New South Wales, Australia
Nepean Hospital /ID# 239093
Kingswood, New South Wales, Australia
Townsville University Hospital /ID# 231124
Douglas, Queensland, Australia
Peninsula Private Hospital /ID# 238796
Frankston, Victoria, Australia
Fiona Stanley Hospital /ID# 231122
Murdoch, Western Australia, Australia
Showing 40 of 273 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.